Experienced in Mononucleosis

Michael E. O'dwyer

Newcastle Road, 
Gaillimh, C, IE 
Experienced in Mononucleosis
Newcastle Road, 
Gaillimh, C, IE 
OverviewLocationsClinical Research

Overview

Michael O'dwyer practices in Gaillimh, Ireland. Mr. O'dwyer is rated as an Experienced expert by MediFind in the treatment of Mononucleosis. His top areas of expertise are Multiple Myeloma, Leukemia, Chronic Familial Neutropenia, and Acute Myeloid Leukemia (AML).

His clinical research consists of co-authoring 91 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Mononucleosis.

Gender
Male

Locations

Newcastle Road, Gaillimh, C, Ireland
Other Locations
Newcastle Road, H91 YR71, Gaillimh, C, Ireland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma
A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma
Enrollment Status: Completed
Publish Date: July 10, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase Ib Study of Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM): The CyBorD-DARA Study
Phase Ib Study of Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM): The CyBorD-DARA Study
Enrollment Status: Unknown
Publish Date: March 29, 2018
Intervention Type: Drug
Study Drugs: Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
Study Phase: Phase 1
View 4 Less Clinical Trials

91 Total Publications

Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the Sialic acid/Siglec axis.
Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the Sialic acid/Siglec axis.
Journal: Journal for immunotherapy of cancer
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. O'dwyer's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile